Myelodysplastic Syndrome-Pipeline Review, H2 2016: Ken Research

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome-Pipeline Review, H2 2016, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.


Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).

The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

Key Topics Covered in the Report:

Myelodysplastic Syndrome Products Glance

Key Players In Myelodysplastic Syndrome Therapeutics

Myelodysplastic Syndrome Market Research Report

Myelodysplastic Syndrome Market Trends

Myelodysplastic Syndrome Overview

Myelodysplastic Syndrome Market Forecast

Myelodysplastic Syndrome Future Projections

Myelodysplastic Syndrome Competition Analysis

Myelodysplastic Syndrome Competitive Landscape

For more coverage click on the link below:

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s